What changed for Mesothelioma
A plain English summary of what recently moved in the public data Voxsanity tracks for Mesothelioma. Updated from government registries. Not medical advice.
How to read these changes: every figure on this page is the difference between two snapshots of what Voxsanity had tracked on each date. Voxsanity only began taking daily snapshots in July 2026 and is still ingesting the public registries, so a rise here is mostly our own coverage expanding rather than new research appearing. Read it as our tracked coverage growing, not as a claim about real-world research changing this fast: it overstates how much actually changed.
Comparing the two most recent snapshots, 27 July 2026 and 28 July 2026.
- Trials recruiting at Australian sites 2 to 3 (+1)
- Trials recruiting worldwide 83 to 84 (+1)
- Trials on record 458 to 468 (+10)
Newly subsidised on the PBS
No PBS-reviewed medicines are tracked for Mesothelioma yet, so new PBS listings cannot be reported for it. This is a gap in what Voxsanity has mapped, not a statement that no medicines are subsidised — check the PBS directly.
Past updates
Tracking began in July 2026. Month on month changes will appear here once a second month of data has been recorded. Until then, the comparison above shows the most recent movement.
Recent trend
Weekly, most recent weeks (fills out to a monthly trend as history grows).
Recent trial results
The 30 most recent of 39 trials tracked for Mesothelioma that have reported results to a public registry.
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
-
NCT05451849 · results posted 13 July 2026
According to the results reported on ClinicalTrials.gov, this was a Phase 1 clinical trial (NCT05451849) testing an experimental treatment called TC-510. A total of 14 people enrolled in the study, though only 6 completed it — 8 participants did not finish, though the reasons are not broken down further in the reported data. The trial was primarily looking at unwanted medical events (called adverse events) that occurred during or after treatment, as well as some early signs of how tumours responded. The reported data shows that, among the 6 participants for whom adverse event data was recorde...
-
NCT04166734 · results posted 4 February 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT04166734) enrolled 5 participants, all in an initial safety group. A planned second group (the "Expansion Cohort") had no participants enrolled. The trial was testing a combination of two treatments — a radiation therapy called SBRT (a focused, high-dose course of radiotherapy given in 3 sessions) and a drug called pembrolizumab — in people with cancer. The main thing the trial was looking to measure was whether the combination caused serious side effects (called "dose limiting toxicities"), with a range of other measures...
-
NCT05070247 · results posted 22 January 2026
According to the results reported on ClinicalTrials.gov, this trial (NCT05070247) tested an investigational drug called TAK-500, given either on its own or in combination with another medicine called pembrolizumab, across a range of doses. The trial enrolled 61 participants in total across 14 treatment groups, with group sizes ranging from 2 to 7 people. No participants had been enrolled yet in the planned "Dose Expansion" group at the time results were submitted. The trial was primarily designed to track what unwanted medical events (called adverse events) occurred after participants received...
-
NCT04914897 · results posted 2 October 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 106 people across four groups. All participants had either non-small cell lung cancer (NSCLC) or mesothelioma (a cancer affecting the lining of the lungs or other organs), and all received a combination of two medicines — pegenzileukin and pembrolizumab. The trial was measuring how many participants' tumours shrank or disappeared (called the "objective response rate"), as well as tracking side effects and how quickly any response appeared. The reported data shows that in the lung cancer group whose tumours had the hi...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT03710876 · results posted 20 May 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT03710876) enrolled 53 people in total — 27 in the Treatment Group and 26 in the Control Group. Four people in the Control Group did not complete the study, while everyone in the Treatment Group did. The trial was measuring how long participants lived overall, how long it took for their disease to get worse, and how their tumours responded to treatment. The reported data shows that the Treatment Group had a median overall survival (that is, the middle point in time by which half the group had passed away) of 17.6 months, c...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT04158141 · results posted 19 February 2025
According to the results reported on ClinicalTrials.gov, this trial (NCT04158141) was designed to study treatments for mesothelioma (a cancer affecting the lining of the lungs) in two steps. In Step 1, all 16 enrolled participants received chemotherapy and a type of surgery called pleurectomy/decortication (removal of the lining around the lung). Eleven of those 16 participants went on to Step 2, where they were randomly assigned to either receive no further treatment (Arm I, 5 participants) or receive a specialised form of radiation therapy called IMRT/PBS (Arm II, 6 participants). The trial...
-
NCT06469138 · results posted 29 January 2025
According to the results reported on ClinicalTrials.gov, this trial enrolled 6 participants, all of whom completed the study. All 6 were in a single group and received one oral dose of 200 mg of a drug called bemcentinib, which contained a small amount of a radioactive tracer (carbon-14). The tracer was used to track how the drug and its breakdown products moved through the body — this type of study is sometimes called a "mass balance" study. The trial was designed to measure how bemcentinib is absorbed, distributed, and cleared from the blood over time. The reported data shows the following...
-
NCT03717415 · results posted 27 December 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03717415) enrolled a total of 70 participants across two main phases. The first phase tested different dose combinations of two medicines — rebastinib (at either 50 mg or 100 mg) and carboplatin (at different dose levels) — to find a suitable dose. The second phase then tested those doses in expanded groups of participants. The trial was measuring things like how many people experienced adverse events (unwanted medical occurrences), how many participants' tumours shrank or disappeared (called the "objective response rate")...
-
NCT01265433 · results posted 9 October 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 41 people in total — 20 received galinpepimut-S combined with two other agents (Montanide and GM-CSF), while 21 received Montanide and GM-CSF alone (the control group). All 41 participants completed the study. The trial was measuring how long people went without their disease getting worse (called progression-free survival), as well as how long people lived overall, and whether the body produced an immune response to the treatment. The reported data shows that, looking at the main outcomes, 44% of people in the galin...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03685591 · results posted 26 June 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03685591) enrolled 49 people in total across nine groups. Participants received the investigational drug PF-06952229 at different dose levels — either on its own (Part 1A, doses ranging from 20 mg to 500 mg) or combined with another drug called enzalutamide (Part 1B, at 250 mg or 375 mg). None of the participants were recorded as having completed the study. The trial was primarily designed to find out how the body tolerates different doses of PF-06952229, by tracking serious side effects (called dose-limiting toxicities) a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03319537 · results posted 23 May 2024
According to the results reported on ClinicalTrials.gov, this trial (NCT03319537) enrolled 9 participants, all of whom were assigned to receive pevonedistat on its own (referred to as Cohort 1). No participants were enrolled in the second group, which was intended to receive pevonedistat combined with two chemotherapy medicines, pemetrexed and cisplatin (Cohort 2). All 9 participants who started the study completed it. The trial was measuring two main things: how many patients in Cohort 1 experienced a "clinical benefit" — meaning their cancer either shrank or stayed stable for at least 18 wee...
-
NCT02004028 · results posted 20 February 2024
According to the results reported on ClinicalTrials.gov, this trial enrolled 35 people across four groups (called cohorts): 10 in Cohort 1, 10 in Cohort 2, 10 in Cohort 3, and 5 in Cohort 4. All 35 participants completed the study. The trial was looking at a drug called defactinib (also known as VS-6063) in people with malignant pleural mesothelioma — a cancer affecting the lining of the lungs. The study measured how the drug moved through the body (pharmacokinetics), whether it reduced the activity of a particular protein in tumour tissue (called pFAK), and how tumours responded on scans. Th...
-
NCT03399552 · results posted 23 October 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03399552) enrolled 15 participants, all of whom received a treatment called avelumab. The trial was measuring what is known as the "overall response rate" — essentially, how many participants' disease changed in a measurable way according to specific imaging guidelines adapted for mesothelioma (a type of cancer affecting the lining of the lungs or abdomen). Of the 15 who started, 13 completed the study and 2 did not finish. The reported data shows the results broken down across four categories of response, with the follow...
-
NCT02709512 · results posted 4 October 2023
According to the results reported on ClinicalTrials.gov, this trial looked at a treatment called ADI-PEG 20 combined with standard chemotherapy (pemetrexed and platinum), compared to a placebo (an inactive substitute) plus the same standard chemotherapy. The trial ran in two stages — a Phase 2 portion (87 people in the ADI-PEG 20 group and 89 in the placebo group) and a Phase 3 portion (125 and 124 people respectively). The main things being measured were how many participants' tumours shrank or disappeared (called the "response rate"), and how long participants lived overall ("overall surviva...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT03926143 · results posted 4 August 2023
According to the results reported on ClinicalTrials.gov, this trial (NCT03926143) enrolled 9 participants, all of whom received a drug called anetumab ravtansine. The trial was measuring side effects experienced during treatment, as well as how long participants lived after starting the treatment. None of the 9 participants formally "completed" the study, as the trial was ended early. The reported data shows that when it came to side effects (called treatment-emergent adverse events, meaning unwanted health changes that started or got worse during the treatment period), all 9 participants exp...
-
NCT03241173 · results posted 27 September 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT03241173) tested an experimental medicine called INCAGN01949, given alone or in combination with other cancer medicines (nivolumab and/or ipilimumab), in people with advanced solid tumours. The trial had two main phases: a Phase 1 portion, which focused on testing different doses and monitoring unwanted medical events, and a Phase 2 portion, which was intended to look at how many participants' tumours responded to treatment. In total, 52 people started the Phase 1 parts of the trial across the various dose groups. The Phas...
-
NCT00738582 · results posted 22 September 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 89 participants, all of whom received a combination of three medicines — amatuximab, pemetrexed, and cisplatin — during an initial treatment phase. Of those 89, 56 went on to a maintenance phase receiving amatuximab on its own, though none were recorded as having fully completed that phase. The trial was primarily measuring how many participants went at least six months without their disease getting worse — a period known as "progression-free survival" — and also tracked a range of other outcomes including tumour resp...
-
NCT02460224 · results posted 10 February 2022
According to the results reported on ClinicalTrials.gov, this trial (NCT02460224) enrolled a total of 512 participants across many different treatment groups. It was a two-phase study testing an experimental drug called LAG525, both on its own and combined with another drug called PDR001, in people with advanced cancer. Phase 1 aimed to find appropriate doses by looking at how many people experienced serious side effects early in treatment (called dose-limiting toxicities — that is, harmful reactions severe enough to limit how much drug could be given). Phase 2 then looked at how many particip...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02592551 · results posted 13 January 2022
According to the results reported on ClinicalTrials.gov, this trial enrolled 24 people in total across three groups: 9 received a drug called MEDI4736 on its own, 11 received a combination of MEDI4736 and a second drug called Tremelimumab, and 4 were in an untreated control group. The trial was measuring changes in certain immune cells found inside tumours — specifically looking at how different types of immune cells behaved before and after treatment. The main thing being measured was the ratio of two types of immune cells (known as CD8 cells and regulatory T cells, or "Tregs") inside the tum...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02899299 · results posted 14 April 2021
According to the results reported on ClinicalTrials.gov, this trial enrolled 605 participants in total — 303 in Treatment A and 302 in Treatment B. The main thing the trial was measuring was **overall survival**, meaning how long participants lived from the time they were randomly assigned to a treatment group. The trial also tracked several secondary measures, including how many participants' tumours shrank or disappeared (called the objective response rate), how many participants had their disease stay stable or improve (called the disease control rate), and how long participants went withou...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02860286 · results posted 9 April 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02860286) looked at a drug called tazemetostat in people with a type of cancer called malignant mesothelioma that had come back or stopped responding to previous treatment. The trial had two parts: Part 1 involved 13 participants and focused on how the drug moves through the body (sometimes called "pharmacokinetics" — meaning how the drug is absorbed, how quickly it reaches its peak level in the blood, and how long it takes to clear). Part 2 involved 61 participants and looked at how the disease responded to the drug. All...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02899195 · results posted 6 April 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT02899195) enrolled 55 participants, all of whom received the immunotherapy drug durvalumab given alongside chemotherapy, followed by durvalumab on its own as a maintenance (ongoing) treatment. The trial was measuring how long participants lived overall, how long they lived without their disease getting worse, and other related outcomes. Of the 55 who started the first phase, 44 moved on to the maintenance phase, and 10 completed that second phase. The reported data shows that the median overall survival — that is, the mid...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT00003508 · results posted 21 February 2021
According to the results reported on ClinicalTrials.gov, this trial (NCT00003508) looked at a treatment called Antineoplaston Therapy. Eight people took part in the study, though only three completed it, and five did not complete it. The trial was measuring how participants' disease responded to the treatment, using standard criteria that categorise responses as a complete response (disease disappearing entirely), a partial response (disease shrinking by at least half), stable disease (disease not changing much), or progressive disease (disease getting worse). The reported data shows that out...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT00128102 · results posted 26 October 2020
According to the results reported on ClinicalTrials.gov, this trial enrolled 329 people in the vorinostat group and 332 in the placebo group — a total of 661 participants. The trial was studying vorinostat as a treatment for pleural mesothelioma (a cancer affecting the lining of the lungs), and it was measuring how long participants lived overall, how long it took for the disease to progress, how many participants showed a measurable reduction in tumour size, and what kinds of unwanted health changes (called adverse events) occurred during the study. The reported data shows that, on average,...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02610140 · results posted 17 July 2020
According to the results reported on ClinicalTrials.gov, this trial compared two treatments — anetumab ravtansine (the experimental drug) and vinorelbine (an existing chemotherapy) — in people with a type of cancer called malignant pleural mesothelioma, a cancer affecting the lining of the lungs. A total of 166 people were assigned to the anetumab ravtansine group and 82 to the vinorelbine group. The trial's main goal was to measure how long participants went without their disease getting worse (called progression-free survival), and a number of secondary goals were also tracked, including how...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02357147 · results posted 17 March 2020
According to the results reported on ClinicalTrials.gov, this trial (NCT02357147) enrolled 108 people with a form of cancer called mesothelioma. Participants were split into two groups: 52 people received a drug called amatuximab combined with two standard chemotherapy medicines (pemetrexed and cisplatin), while 56 people received a dummy treatment (placebo) combined with the same two chemotherapy medicines. The trial was carried out in two phases — a combination treatment phase and a maintenance (ongoing) treatment phase — and the main thing being tracked was how many participants experienced...
Read the full trial page · View reported results on ClinicalTrials.gov ↗
-
NCT01583686 · results posted 9 October 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 15 people in total, with 3 participants placed into each of five groups. Each group received a different dose of a specialised cell-based treatment — called an anti-mesothelin CAR (immune cells that were modified in the laboratory to target a protein found on certain tumours) — alongside a drug called IL-2. All 15 participants completed the study. The trial was primarily measuring two things: whether any participants' tumours shrank or disappeared, and how many participants experienced unwanted medical events (called...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02187783 · results posted 16 April 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled 106 participants, all of whom received a medicine called ribociclib at a dose of 600 mg. The trial was studying how participants' solid tumours responded to this treatment over time. The main things being measured were: how many participants had their tumour shrink or stay stable for at least 16 weeks (called "clinical benefit"), how many had their tumour shrink by a meaningful amount (called "overall response"), and how long participants lived without their disease getting worse or how long they survived overall. Th...
-
NCT01907100 · results posted 18 March 2019
According to the results reported on ClinicalTrials.gov, this trial enrolled a total of 545 participants across two phases. In Phase II, 43 people were assigned to placebo and 44 to nintedanib. In Phase III, 229 people were assigned to each group. The trial was looking at nintedanib (a type of cancer medicine) added to standard chemotherapy, compared to chemotherapy plus a placebo (an inactive treatment), in people with a type of lung cancer. The main thing being measured was how long people lived without their cancer getting worse — called "progression-free survival" — and a key secondary mea...
Read the full trial page · View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
-
NCT02349412 · results posted 28 February 2019
According to the results reported on ClinicalTrials.gov, this trial (NCT02349412) enrolled 405 people with advanced cancer — 202 in the "early palliative care" group, who received palliative care support alongside their usual cancer treatment, and 203 in the "usual care" group, who received standard cancer treatment only. The trial's main goal was to measure any change in participants' quality of life (QOL) over time using a questionnaire called the FACT-G, which runs on a scale of 0 to 108 (higher scores mean better quality of life). Secondary goals included looking at changes in depression a...
View reported results on ClinicalTrials.gov ↗ · Linked publication on PubMed ↗
See all 39 reported results for Mesothelioma
These are the results as reported to the registry, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
What is coming
AI generated pipeline summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to NIH funding data, public research investment in mesothelioma sits at a moderate level, which suggests the condition has attracted meaningful attention from publicly funded science in the United States. However, the direction of that funding is falling year on year, meaning the financial support behind new research appears to be declining rather than growing. For patients, this is a si...
See the full Mesothelioma page
Not medical advice. Voxsanity republishes public government health data in plain English. These figures describe research and registry activity, not the suitability of any treatment for any person. Trial status can change; always verify current status directly with the trial site and confirm Australian availability with your doctor.